What is more, our further studies should, firstly, focus on the use of SIRT3 to predict NSCLC patient survival and to select the patients who will benefit from specific treatments and, secondly, focus on the development of targeted SIRT3 therapies to design personalized treatments. Here, SIRT3 is linked to non-small cell lung carcinoma.